MAPT and Alzheimer disease: For trial enrichment, blood‐based biomarkers can first help identify individuals with a high probability of having AD pathology—for instance, using plasma Aβ42/Aβ40 or P‐tau (Palmqvist et al, 2019b; Janelidze et al, 2020a).